Publication | Closed Access

Phase II, two-arm RTOG trial (94-11) of bischloroethyl-nitrosourea plus accelerated hyperfractionated radiotherapy (64.0 or 70.4 Gy) based on tumor volume (> 20 or ≤ 20 cm2, respectively) in the treatment of newly-diagnosed radiosurgery-ineligible glioblastoma multiforme patients

Adaptive RadiotherapyNeuro-oncologyTwo-arm Rtog TrialPhase IiRadiation TherapyMedicineHigh-grade GliomasRadiation OncologyOncologyGliomaTumor VolumeRadiologyHealth Sciences